Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

阿糖胞苷 医学 去甲柔比星 内科学 养生 髓系白血病 化疗方案 胃肠病学 肿瘤科 不利影响 化疗 外科
作者
Christian Récher,Jenny O’Nions,Ibrahim Aldoss,Ana Alfonso Piérola,Alicia J. Allred,Juan Manuel Alonso‐Domínguez,Laura Barreyro,Pierre Bories,Martin Curtis,Nikki Daskalakis,Matteo Giovanni Della Porta,Hartmut Döhner,Amber D'Souza,James P. Dugan,Jordi Esteve Reyner,Matthew Exum,Amir T. Fathi,Pasquale L. Fedele,Lucille Ferrante,Stan Gaj
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 215-215 被引量:23
标识
DOI:10.1182/blood-2024-207072
摘要

Background: Newly diagnosed (ND) acute myeloid leukemia (AML) is a genetically heterogeneous disease with a median 5-year overall survival of approximately 30%. Combining standard intensive chemotherapy (IC) approaches with targeted therapies may further improve outcomes. Bleximenib is a potent, selective menin-KMT2A complex inhibitor with activity in NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) AML when given either as monotherapy or in combination for relapsed/refractory disease (Jabbour et al., ASH 2023; Wei et al., EHA 2024). The focus of this study has been to explore the safety and preliminary efficacy of combining bleximenib with IC for ND AML. Aims: To determine the safety and preliminary efficacy of bleximenib in combination with intensive cytarabine + daunorubicin/idarubicin, followed by cytarabine consolidation for ND NPM1m or KMT2Ar AML participants (pts) eligible for IC. Methods: NCT05453903 is an ongoing Phase 1b, multicenter, dose-finding study. In dose escalation, pts received a standard '7+3' regimen of cytarabine 200mg/m2/day and daunorubicin 60mg/m2/day IV or idarubicin 12mg/m2/day IV. Bleximenib was administered orally, twice daily (BID), and dosed continuously. Pts who achieved a complete remission (CR) received consolidation therapy with up to 4 cycles of intermediate-dose cytarabine plus bleximenib. Those not proceeding to allogeneic hematopoietic stem cell transplant could receive bleximenib continuation for up to 12 months. As of July 16th 2024, bleximenib doses ≥30 mg BID have been explored in combination with '7+3' IC. The safety dataset includes all dosed pts, with adverse events (AEs) reported per CTCAE v5. The efficacy dataset, as assessed by investigators (per modified ELN 2017), comprises ND pts with NPM1m or KMT2Ar who received ≥50 mg bleximenib BID in combination with '7+3' IC and completed at least 1 disease evaluation. Results: In the safety dataset, 22 ND AML pts (median age: 58 [27-70] years; 54.5% female, 45.5% male; 11 NPM1, 11 KMT2A altered) received bleximenib across dose levels explored in combination with IC. 95% (21/22) of pts had ≥1 treatment-emergent AE (TEAE, all grades): diarrhea (17/22; 77%), thrombocytopenia (15/22; 68%), febrile neutropenia (14/22; 64%), pyrexia (13/22; 59%), anemia and nausea (11/22; 50% each) were the most common. Grade ≥3 TEAEs also occurred in 95% (21/22) of pts; the most frequent events were febrile neutropenia (14/22; 64%), thrombocytopenia (15/22; 68%), anemia, neutropenia (9/22; 41% each) and leukopenia (6/22; 27%). TRAEs (all grades) attributed to bleximenib alone occurred in 18% (4/22) of pts, including thrombocytopenia and neutropenia (2/22; 9% each) and single cases (5% each) of anemia, diarrhea, cerebrovascular accident, dysesthesia and upper abdominal pain. Grade ≥3 TRAEs attributed to bleximenib alone occurred in 14% (3/22) of pts, including thrombocytopenia (2/22; 9%) and single cases (5% each) of anemia and neutropenia. No differentiation syndrome (DS) or dose-limiting toxicities (DLTs) were observed. Two episodes of Grade 1 QTcF prolongation were recorded but not attributed to bleximenib. In pts who achieved initial blast clearance, the median time from Day 1 of induction to platelet count recovery (50x109/L) was 32 days (range, 22-45), and the median time to neutrophil count recovery (0.5x109/L) was 32 days (range, 25-45). The efficacy dataset includes 14 pts (8 NPM1m, 6 KMT2Ar). In this population, overall response rate (ORR: ≥PR) was 93% (79% CR; 86% CR/CRh) and median time to CR was 30 days (range, 22-41). By genotype, the ORR was 83% in pts with KMT2Ar AML (83% CR/CRh) and 100% in pts with NPM1m (88% CR/CRh). Of those pts who have completed consolidation therapy, five have proceeded to allogeneic hematopoietic stem cell transplantation. Summary/Conclusion: Dose escalation is ongoing in this Phase 1b study. Preliminary results demonstrate that bleximenib in combination with ‘7+3‘ IC regimen in ND AML pts eligible for such therapy has an acceptable safety profile with no DS or DLTs observed. There is no consistent delay in neutrophil or platelet count recovery after induction. In addition, preliminary antileukemic activity is observed in pts with ND NPM1m or KMT2Ar AML treated with bleximenib in combination with IC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
多情莫言完成签到,获得积分10
刚刚
3秒前
害羞的雁易完成签到 ,获得积分10
5秒前
哈哈哈完成签到 ,获得积分10
5秒前
wxm完成签到,获得积分10
9秒前
猪猪hero发布了新的文献求助10
9秒前
luo完成签到,获得积分10
11秒前
CY完成签到,获得积分10
12秒前
vtd完成签到 ,获得积分10
14秒前
CipherSage的应助被岁见采纳,获得10
14秒前
14秒前
SongXJ完成签到 ,获得积分10
18秒前
科研小白完成签到 ,获得积分10
18秒前
xwq完成签到,获得积分10
19秒前
KINGAZX完成签到 ,获得积分10
21秒前
漾漾的羊完成签到 ,获得积分10
26秒前
新帅完成签到,获得积分10
27秒前
arniu2008发布了新的文献求助10
35秒前
35秒前
黑米粥发布了新的文献求助30
38秒前
Waiting完成签到 ,获得积分10
38秒前
42秒前
复杂芷文完成签到,获得积分10
43秒前
MM完成签到 ,获得积分10
43秒前
ty完成签到 ,获得积分10
45秒前
猪猪hero完成签到,获得积分10
46秒前
潮哥完成签到 ,获得积分10
47秒前
岁见发布了新的文献求助10
50秒前
秀丽颤完成签到,获得积分10
52秒前
52秒前
53秒前
Harlotte完成签到 ,获得积分0
55秒前
慕青的应助被霖29采纳,获得10
55秒前
黑米粥发布了新的文献求助200
56秒前
58秒前
cloud完成签到 ,获得积分10
1分钟前
李健的应助被岁见采纳,获得10
1分钟前
酷酷的幼菱完成签到 ,获得积分10
1分钟前
1分钟前
黑米粥发布了新的文献求助200
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185501
求助须知:如何正确求助?哪些是违规求助? 9574179
关于积分的说明 21834528
捐赠科研通 7783108
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481357